QLS-5132

N/A

Report date: 2026/04/07 20:00:20

Base Information

Drug NameQLS-5132
Drug Alias NameQLS5132QLS-5132
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN6
TargetsClaudin 6
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A